

## ПАТЕНТЫ/PATENTS


Чтобы ознакомиться с полными текстами зарубежных патентов, следует пройти по ссылке [https://ru.espacenet.com/?locale=ru\\_RU](https://ru.espacenet.com/?locale=ru_RU) с указанием номера документа, отраженного в реферате

SI3099217 (T1) — 2018-10-30

US10111583 (B1) — 2018-10-30

### NON-INVASIVE COMPRESSION AND REFRACTION CONTACT TONOMETER FOR MEASURING THE PRESSURE IN THE POSTERIOR CHAMBER AND/OR THE VITREOUS CHAMBER OF THE EYE

A non-invasive contact compression and refraction tonometer for measuring the intraocular pressure of the posterior chamber of the eye, measuring pressure in the posterior chamber of the eye and the vitreous chamber of the eye characterized by the fact that it is a device which measures intraocular pressure in the posterior chamber of the eye and the vitreous chamber of the eye in a compression and contract manner in relation to the walls of the posterior chamber with a double symmetrical compression element, operating concentrically, and driven by a compression actuator coupled with a newton meter, measuring the compression force necessary to deform the cornea in order to achieve the assumed corneal astigmatism level, which is measured on the cornea with an optic meter in a non-contact manner in relation to the cornea. The force of mutual impressions of the wall of the posterior chamber (compression) corresponds to the intraocular pressure in the posterior chamber of the eyeball compressed with a given force and surface in accordance with the Imbert — Fick principle.



### SYSTEM, METHOD, AND NON-TRANSITORY COMPUTER-READABLE STORAGE MEDIA RELATED TO CORRECTION OF VISION DEFECTS USING A VISUAL DISPLAY

Techniques related to vision correction are disclosed. The techniques involve establishing a visual model associated with a patient. The visual model includes data related to a quality of the patient's vision. A boundary is established as a function of the data associated with the visual model. The boundary is indicative of an area to be corrected within the patient's vision. A retinal map is established as a function of the boundary. An image from a camera associated with the patient is captured and corrections are applied to the image based on the retinal map to generate a corrected image. The corrected image is presented to the eye of the patient.

LT2915529 (T) — 2018-10-25

### THERAPEUTIC REPLENISHMENT AND ENRICHMENT OF OCULAR SURFACE LUBRICATION

Provided herein are ophthalmically acceptable pharmaceutical compositions comprising a PRG4 inducing compound in combination with PRG4 (including a lubricant fragments, homologs, or isoforms thereof), and methods of using the same. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e. g., ocular boundary deficiency and symptoms associated therewith.

PH12018500745 (A1) — 2018-10-15

### HIGH-DOSE STATINS FOR AGE-RELATED MACULAR DEGENERATION

Methods of using a high-dose statin for treatment of AMD in a patient can be used to regress drusen and/or drusenoid pigment epithelial detachments (PEDs), to prevent atrophy of the RPE and/or one or more photoreceptors, to prevent vision loss and/or improve visual acuity, and/or to prevent progression from dry AMD to wet AMD.

## ПАТЕНТЫ/PATENTS

AU2017250797 (A1) — 2018-10-25

WO2018194889 (A1) — 2018-10-25

**TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB**

Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”) — such as, e. g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment — to the retina/vitreous humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.

**COMMENSAL BACTERIA AS NOVEL TREATMENT FOR DRY EYE AND SJOGREN SYNDROME**

Embodiments of the disclosure encompass methods of treating or preventing an autoimmune disease in an individual. In particular cases, methods comprise administering for delivery to an individual a composition of microbiota. In certain cases, the composition comprises a population of one or more microbiota capable of producing one or more short-chain fatty acids.



официальный  
дистрибьютер  
**Alcon®**

Система  
офтальмологическая  
**CENTURION®**  
Vision System




Система 3D  
визуализации  
**NGENUITY®**



**Хирургическое,  
диагностическое оборудование  
и расходные материалы  
для офтальмологии**

Система  
офтальмологическая  
лазерная фемтосекундная  
**WaveLight® FS200**



Система  
офтальмологическая  
**CONSTELLATION®**  
Vision System

